NCT05629468

Brief Summary

the goal of this clinical trial is to measure the efficacy of probiotics for treatment of acne vulgaris, to compare it with azithromycin and to measure the synergistic effect of azithromycin and probiotics for treatment of acne vulgaris

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Oct 2021

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 9, 2022

Completed
20 days until next milestone

First Posted

Study publicly available on registry

November 29, 2022

Completed
Last Updated

December 5, 2022

Status Verified

November 1, 2022

Enrollment Period

9 months

First QC Date

November 9, 2022

Last Update Submit

November 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • change or reduction in the Total Lesion Count

    number of acne lesions are counted at every follow up to see whether lesions are reduced than the baseline or not

    at start of the study (baseline), 2 weeks (1st follow up visit), 4 weeks (2nd follow up visit), 8 weeks (3rd follow up visit) and 12 weeks (4th follow up visit).

Secondary Outcomes (1)

  • change or reduction in the Dermatology Life Quality Index score

    at start of the study (baseline) and 12 weeks (last follow up visit).

Study Arms (3)

Azithromycin and Topical

ACTIVE COMPARATOR

group A (n=25) received tab. azithromycin 250mg oral on alternate days and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months

Drug: AzithromycinDrug: Benzoyl Peroxide 4 % Topical Cream

Probiotics and Topical

EXPERIMENTAL

group B (n=25) received Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months

Drug: Probiotic FormulaDrug: Benzoyl Peroxide 4 % Topical Cream

Azithromycin and Probiotics and Topical

OTHER

combination group C (n=25) received tab. azithromycin 250mg oral on alternate days, Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months

Drug: AzithromycinDrug: Probiotic FormulaDrug: Benzoyl Peroxide 4 % Topical Cream

Interventions

antibiotic

Also known as: "Zetro" by "Getz Pharma"
Azithromycin and Probiotics and TopicalAzithromycin and Topical

probiotics

Also known as: "Hi-Flora" by "Unicare Bioceuticals"
Azithromycin and Probiotics and TopicalProbiotics and Topical

topical cream

Also known as: "Benoxyl" by "Glitz pharma"
Azithromycin and Probiotics and TopicalAzithromycin and TopicalProbiotics and Topical

Eligibility Criteria

Age15 Years - 35 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Diagnosed Patients of Mild and Moderate acne
  • Aged between 15 and 35 years

You may not qualify if:

  • Severe acne or any systemic inflammatory disease
  • Other oral treatment for acne
  • Allergic to any drug being used in the study
  • Pregnancy
  • PCOs
  • Any drug which can interact with azithromycin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

PEMH

Rawalpindi, Punjab Province, 46000, Pakistan

Location

MeSH Terms

Conditions

Acne Vulgaris

Interventions

AzithromycinBenzoyl Peroxide

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

ErythromycinMacrolidesPolyketidesLactonesOrganic ChemicalsBenzoatesAcids, CarbocyclicCarboxylic AcidsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Akbar W Syed, PhD

    Riphah International University, Islamabad

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prinicipal Investigator

Study Record Dates

First Submitted

November 9, 2022

First Posted

November 29, 2022

Study Start

October 15, 2021

Primary Completion

June 30, 2022

Study Completion

August 31, 2022

Last Updated

December 5, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations